Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells

European Journal of Nuclear Medicine

Volumn 24, Issue 5, 1997, Pages 538-543

  Babich, John W ^a,b   Graham, Wendy ^a   Fischman, Alan J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adrenergic receptor ligands; Metaiodobenzylguanidine uptake; Neuroblastoma cells; Storage

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; ADRENERGIC RECEPTOR; ATENOLOL; CLONIDINE; GUANETHIDINE; LABETALOL; LIGAND; METHOXAMINE; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; PROPRANOLOL; RADIOPHARMACEUTICAL AGENT; TOLAZOLINE; XYLAZINE; YOHIMBINE;

ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; SCINTIGRAPHY; STORAGE;

EID: 0030950342     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01267686     Document Type: Article

References (50)

1. Wieland D, Wu J, Brown L, Mangner T, Swanson D, Beierwaltes W. Radiolabelled adrenergic neuron-blocking agents: adrenomedullary imaging with I-131 iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.
2. Wieland D, Brown L, Rogers W, Worthington K, Wu J, Clinthorne N, Otto C, Swanson D, Beierwaltes W. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22: 22-31.
3. 123I]iodobenzylguanide: concise communication. J Nucl Med 1984; 25: 436-440
4. Sisson J, Shapiro B, Beierwaltes W, Glowniak J, Nakajo M, Mangner T, Carey J, Swanson D, Copp J, Satterlee W, Wieland D. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984; 25: 197-206.
5. McEwan A, Shapiro B, Sisson J, Beierwaltes W, Ackery D. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumours. Semin Nucl Med 1985; 15: 132-153.
6. Kimmig B, Brandeis W, Eisenhut M, Bubeck B, Hermann H, z. Winkel K. Scintigraphy of a neuroblastoma with 131 meta-iodobenzylguanidine. J Nucl Med 1984; 25: 773-775.
7. Hoefnagel C, Voute P, deKraker J, Marcuse H. Total-body scintigraphy with 131-meta-iodobenzylguanidine for detection of neuroblastoma. Diagn Imag Clin Med 1985; 54: 21-27.
8. Troncone L, Rufini V, Montemaggi P, Danza F, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radio-iodinated metaiodobenzylguanidine (MIBG). Eur J Nucl Med 1990; 16: 325-335.
9. 131I-mIBG imaging of carcinoid tumors and apudomas. J Nucl Med 1984; 25: 1221-1222.
10. 123I meta-iodobenzylguanidine (MIBG) scintigraphy of retino-blastoma: preliminary experience. Br J Ophthalmol 1989; 73: 146-150.
11. Osei-Bonsu A, Kokoschka EM, Ulrich W, Sinzinger H. I-131-metaiodobenzylguanidine (mIBG) for bronchial oat cell cancer and melanoma detection? Eur J Nucl Med 1989; 15: 629-631.
12. 131I MIBG imaging in small cell lung carcinoma [letter]. J Nucl Med 1987; 28: 1230.
13. Deacon J, Wilson P, Peckham M. The radiobiology of human neuroblastoma. Radiother Oncol 1985; 3: 201-209.
14. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meiler S, Kemshead JT, Ackery D. Phase I/II study of iodine 131 meta-iodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992; 10: 1889-1896.
15. Jaques S, Tobes M, Sisson J, Baker J, Wieland D. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984; 26: 539-546.
16. Tobes M, Jaques S, Wieland D, Sisson J. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985; 26: 897-907.
17. Insel P. Adrenergic receptors. Am J Hypertens 1989; 2: 112S-118S.
18. Rand MJ, McCulloch MW, Story DF. Catecholamine receptors on nerve terminals. In: Szekeres L, ed. Adrenergic activators and inhibitors. Berlin Heidelberg New York; 1980: 223 (Handbook of Experimental Pharmacology, vol 541)
19. Rand MJ, McCulloch MW, Story DF. Catecholamine receptors on nerve terminals. In: Szekeres L, ed. Adrenergic activators and inhibitors. Berlin Heidelberg New York; 1980: 223 (Handbook of Experimental Pharmacology, vol 541)
20. 2-ovadrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci 1988; 9: 356-361.
21. Adler-Graschinsky E, Langer SZ. Possible role of a β-adrenoceptor in the regulation of noradrenaline release by nerve stimulation through a possible feedback mechanism. Br J Pharmacol 1975; 53: 43.
22. 2-adrenoceptors in the anaesthetized dog. Can J Physiol Pharmacol 1987; 65: 550-557.
23. 2-adrenoceptors at the level of the adrenal medulla. Can J Physiol Pharmacol 1988; 66: 1340-1343.
24. Foucart S, Nadeau R, DeChamplain J. Local modulation of adrenal catecholamines release by beta-2 adrenoceptors in the anaesthetized dog. Arch Pharm (Weinheim) 1988; 337: 29-34.
25. 2-adrenergic and muscarinic cholinergic receptors have opposing actions on cyclic AMP levels in SK-N-SH human neuroblastoma cells. J Neurochem 1989; 53: 602-609.
26. 2-adrenergic receptor sites in human retinoblastoma (Y-79) and neuroblastoma (SH-SY5Y) cells. Biochem Biophys Res Commun 1989; 158: 921-920.
27. Feusner J, O'Leary M, Beach B. Hypertension in neuroblastoma induced by imipramine. Am J Pediatr Hematol Oncol 1987; 9: 305-307.
28. Mangner T, Wu J, Wieland D. Solid-phase exchange radioiodination of aryl iodides. Facilitation by ammonium sulfate. J Org Chem 1982; 47: 1484-1488.
29. 124I-MIBG positron emission tomography. Br J Radiol 1992; 65: 787-791.
30. Biedler J, Spengler B, Ross R. Cellular maturation and oncogene expression during drug-induced differentiation in vitro: a brief review. Eff Ther Biol Kin Res Tum 1990; A: 287-312.
31. Duncan DB. Multiple range tests and multiple F-tests. Biometrics 1955; 11: 1-42.
32. Bruchelt G, Girgert R, Buck J, Wolburg H, Niethammer D, Treuner J. Cytotoxic effects of m-I-131 and m-I-125 iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO. Cancer Res 1988; 48: 2993-2997.
33. Moyes J, Babich J, Carter R, Meiler S, Agrawal M, McElwain T. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumour histopathology. J Nucl Med 1989; 30: 474-480.
34. 131I-meta-iodobenzylguanidine. Nucl Med 1986; 25: 172-175.
35. 131I-radiolabelled meta-iodo-benzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma. Br J Radiol 1991; 53: 210-227.
36. Lemmer B, Wiethold G, Hellenbrecht D, Bak I, Grobecker H. Human blood platelets as cellular models for investigation of membrane active drugs: beta-adrenergic blocking agents. Arch Pharm (Weinheim) 1972; 275: 299-313.
37. Paton DM. Characteristics of uptake of noradrenaline by adrenergic neurons. In: Paton DM, ed. The mechanism of neuronal and extraneuronal transport of catecholamines. New York: Raven Press; 1976: 25-35.
38. Rang HP, Dale MM. Adrenergic transmission. In: Pharmacology. New York: Churchill Livingstone; 1987: 163-167.
39. 131I]meta-iodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med 1991; 35: 308-312.
40. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989; 30: 481-489.
41. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radio-iodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994; 21: 545-559.
42. 131I]meta-iodobenzylguanidine: concise communication. J Nucl Med 1981; 22: 358-364.
43. Knoben JE, Anderson PO, Watanabe AS. Handbook of clinical drug data, 4th edn. Hamilton, Ill.: Drug Intelligence Publications; 1978: 299.
44. Smets L, Loesberg C, Janssen M, Metwally E, Huiskamp R. "Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989; 49: 2941-2944.
45. Baulieu J, Huguet F, Chalon S, Gerard P, Frangin Y, Besnard J, Pourcelot L, Guilloteau D. I-125 MIBG uptake and release in different regions of the rat brain. Nucl Med Biol 1990; 17:511-514.
46. Guilloteau D, Huguet F, Chalon S, Baulieu J, Gerard P, Narcisse G, Pourcelot L, Besnard J. MIBG and catecholamine storage in the brain: an in-vitro study. Nucl Med Biol 1988; 15: 723-724.
47. Fuder H, Bath F, Wiebelt H, Muscholl E. Autoinhibition of noradrenaline release from the rat heart as a function of the biophase concentration. Effects of exogenous α-adrenoceptor agonists, cocaine, and perfusion rate. Arch Pharm (Weinheim) 1984; 325: 25-33.
48. Bomanji J, Levison D, Flatman W, Home T, Bouloux P, Ross G, Britton K, Besser G. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med 1987; 28: 973-978.
49. Robbins SL, Cotrna RS, Kumar V. Pathological basis of disease, 3rd edn. Philadelphia: Saunders; 1984: 1244-1248.
50. Nakajo M, Shapiro B, Glowniak J, Sisson J, Beierwaltes W. Inverse relationship between cardiac accumulation of meta-[131]iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med 1983; 24: 1127-1134.